Abstract
After disappointing results achieved with older chemosensitivity tests such as the human tumor clonogenic assay (HTCA) during the 1980s, the last decade has seen a renaissance of the concept of individualized chemotherapy in oncology, markedly stimulated by the development of newer nonclonogenic assays. These methods appear to be able to overcome major technical limitations associated with older assays, now allowing for successful testing of most of the tumor specimens submitted. Currently, the ATP-based tumor chemosensitivity assay (ATP-TCA) can be regarded as the most sophisticated assay to investigate both solid samples and effusions derived from patients with various organ tumors.
During the last 5 years, the ATP-TCA has been used successfully to screen for novel drug combinations for further clinical use in both ovarian and breast cancer such as mitoxantrone plus paclitaxel (NT) and treosulfan plus gemcitabine (TG), respectively. Clinical trials that have been set up in heavily pretreated patients with recurrent ovarian or breast cancer have convincingly confirmed the high activity of these combinations previously demonstrated in preclinical investigations using the ATP-TCA. In a recent phase II trial performed in 59 patients with relapsed ovarian carcinoma, |ATP-TCA-directed therapy was able to triple the response rate and to double the survival time, compared with published empirical chemotherapy regimes. Preliminary results with ATP-TCA-directed therapy in breast cancer also evidenced promising response rates. These results have been confirmed by additional prospective clinical trials using other types of modern nonclonogenic assays. A phase III trial that is now actively recruiting patients with platinum-refractory ovarian cancer to verify the promising phase II studies will prove the further value of the ATP-TCA as a predictor applicable in routine clinical oncology.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bellamy WT (1992) Prediction of response to drug therapy of cancer. A review of in vitro assays. Drugs 44:690–708
Cree IA, Kurbacher CM (1997) Individualizing chemotherapy for solid tumors — is there any alternative? Anti-Cancer Drugs 8:541–548
DeVita VT (1997) Principles of cancer management: chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 5th edn. Lippincott-Raven, Philadelphia, pp 333–347
Hamburger AW, Salmon SE (1977) Primary bioassay of human tumor stem cells. Science 197:161–163
Von Hoff DD (1990) He’s not going to talk about in vitro predictive assays again, is he? J Natl Cancer Inst 82:97–101
Cortazar R, Johnson BE (1999) Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. J Clin Oncol 17:1625–1631
Brown E, Markman M (1996) Tumor chemosensitivity and chemoresistance assays. Cancer 77:1020–1025
Andreotti PE, Cree IA, Kurbacher CM et al (1995) Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 55:5276–5282
Cree IA, Kurbacher CM, Untch M et al (1996) Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anti-Cancer Drugs 7:630–635
Konecny G, Cohns C, Pegram M et al (2000) Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol 77:258–263
Kurbacher CM, Bruckner HW, Cree IA et al (1997) Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial. Clin Cancer Res 3:1527–1533
Janát M, Kurbacher CM, Rein D et al (2000) Mitoxantrone plus paclitaxel: a highly active regimen for heavily pretreated ovarian cancer. Proc Am Soc Clin Oncol 19:384a
Flaskamp C, Köhler S, Kurbacher C et al (1998) Kombinationschemotherapie des rezidivierten Ovarialkarzinoms mit Mitoxantron und Paclitaxel. Arch Gynecol Obstet 261 (Suppl 1):S17
Salimichokami M (2001) Weekly paclitaxel and mitoxantrone: a highly active salvage regimen for recurrent ovarian cancer. Proc Am Soc Clin Oncol 20:214a
Neale MH, Myatt N, Cree IA et al (1999) Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. Br J Cancer 79:1487–1493
Cree IA, Neale MH, Myatt NE et al (1999) Heterogeneity of chemosensitivity of metastatic cutaneous melanoma. Anti-Cancer Drugs 10:437–444
Grecu OM, Kurbacher CM, Mallmann P et al (2001) Treosulfan and gemcitabine in heavily pretreated patients with breast and ovarian cancer: laboratory study and clinical pilot trial of the ISCO Clinical Study Group. Proc Am Soc Clin Oncol 20:187b
Grecu OM, Kurbacher CM, Stier U et al (2001) Salvage therapy of patients with heavily pretreated breast and ovarian carcinoma: a clinical pilot trial based on results of an ex vivo study. Anti-Cancer Drugs 12 (Suppl 4):A15
Nagourney RA, Su YZ, Link J et al (1998) Gemcitabine synergy with cisplatin. Clinical and laboratory correlates. Proc Am Assoc Cancer Res 39:310
Nagourney RA, Link JS, Blitzer JB et al (2000) Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol 18:2245–2249
Kurbacher CM, Cree IA, Bruckner HW et al (1998) Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anti-Cancer Drugs 9:51–57
Kurbacher CM, Stier U, Janát M et al (2001) ATP-assay-directed chemotherapy for recurrent ovarian cancer: mature results of an ISCO Clinical Study Group Trial. Proc Am Soc Clin Oncol 20:184b
Kurbacher CM (2001) ATP chemosensitivity testing in ovarian cancer: early clinical trials. Anti-Cancer Drugs 12 (Suppl 4):A14
Dottino R, Evans SS, Segna R et al (2000) EVA-assay directed therapy of advanced ovarian cancer. Proc Amer Soc Clin Oncol 19:387a
Kurbacher CM, Janát MM, Brenne U et al. Chemosensitivitätstestung beim Mammakarzinom. In: Untch M, Konecny G, Sittek H, et al (eds) Diagnostik und Therapie des Mammakarzinoms — State of the Art 2000. Zuckschwerdt, Munich
Xu JM, Song ST, Zang ZM et al (1999) Predictive chemotherapy of advanced breast cancer directed by MTT assay in vitro. Breast Cancer Res Treat 53:77–85
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Kurbacher, C.M. et al. (2003). ATP Chemosensitivity Testing in Ovarian and Breast Cancer: Early Clinical Trials. In: Reinhold, U., Tilgen, W. (eds) Chemosensitivity Testing in Oncology. Recent Results in Cancer Research, vol 161. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-19022-3_17
Download citation
DOI: https://doi.org/10.1007/978-3-642-19022-3_17
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62412-4
Online ISBN: 978-3-642-19022-3
eBook Packages: Springer Book Archive